

# Suraksha Clinic & Diagnostics

## SURAKSHA DIAGNOSTIC LIMITED



(Please scan this QR code to view the Prospectus)

Our Company was incorporated as 'Suraksha Diagnostic Private Limited' as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata. Subsequently, our Company was converted into a public limited company pursuant to a special resolution passed in the extra-ordinary general meeting of our Shareholders held on June 5, 2024, and consequently, the name of our Company was changed to 'Suraksha Diagnostic Limited', and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre. For details of changes in the name and registered and corporate office address of our Company, see 'History and Certain Corporate Matters' on page 254 of the Prospectus.

Registered and Corporate Office: Plot No. DG-12/1, Action Area 1D, Premises No. 02-0327, New Town, Rajarhat, Kolkata - 700 156 West Bengal, India; Tel: +91 33 66059750. Contact Person: Mamta Jain, Company Secretary and Compliance Officer  
E-mail: investors@surakshanet.com; Website: www.surakshanet.com; Corporate Identity Number: U85110WB2005PLC102265

### PROMOTERS OF OUR COMPANY: DR. SOMNATH CHATTERJEE, RITU MITTAL AND SATISH KUMAR VERMA

Our Company has filed the prospectus dated December 3, 2024 (the "Prospectus") with the RoC and the Equity Shares are proposed to be listed on the Main Board of the Stock Exchanges and the trading is expected to commence on Friday, December 6, 2024.

### BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 19,189,330 EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH OF SURAKSHA DIAGNOSTIC LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹441 PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹439 PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING TO ₹8,462.49 MILLION THROUGH AN OFFER FOR SALE OF 19,189,330 EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AGGREGATING TO ₹8,462.49 MILLION, COMPRISING 2,132,148 EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AGGREGATING TO ₹940.28 MILLION BY DR. SOMNATH CHATTERJEE, 2,132,148 EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AGGREGATING TO ₹940.28 MILLION BY RITU MITTAL, 2,132,148 EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AGGREGATING TO ₹940.28 MILLION BY SATISH KUMAR VERMA (WHOSE SHARES ARE JOINTLY HELD WITH SUMAN VERMA) (TOGETHER WITH DR. SOMNATH CHATTERJEE AND RITU MITTAL, THE "PROMOTER SELLING SHAREHOLDERS"), 10,660,737 EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AGGREGATING TO ₹4,701.39 MILLION BY ORBIMED ASIA II MAURITIUS LIMITED<sup>^</sup> (THE "INVESTOR SELLING SHAREHOLDER"), 799,556 EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AGGREGATING TO ₹352.60 MILLION BY MUNNA LAL KEJRIWAL, AND 1,332,593 EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AGGREGATING TO ₹587.67 MILLION BY SANTOSH KUMAR KEJRIWAL (TOGETHER THE "INDIVIDUAL SELLING SHAREHOLDERS") (THE PROMOTER SELLING SHAREHOLDERS, THE INVESTOR SELLING SHAREHOLDER AND THE INDIVIDUAL SELLING SHAREHOLDERS, COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS", AND SUCH EQUITY SHARES OFFERED BY THE SELLING SHAREHOLDERS, THE "OFFERED SHARES") (THE "OFFER" OR THE "OFFER FOR SALE"). THE OFFER CONSTITUTES 36.84% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

<sup>^</sup> SURVIVING ENTITY PURSUANT TO AMALGAMATION OF ORBIMED ASIA II MAURITIUS FDI INVESTMENTS LIMITED, THE ERSTWHILE SHAREHOLDER, INTO ORBIMED ASIA II MAURITIUS LIMITED ON NOVEMBER 11, 2022

**ANCHOR INVESTOR OFFER PRICE: ₹ 441 PER EQUITY SHARE OF FACE VALUE OF ₹ 2 EACH**  
**OFFER PRICE: ₹ 441 PER EQUITY SHARE OF FACE VALUE OF ₹ 2 EACH**  
**THE OFFER PRICE IS 220.50 TIMES THE FACE VALUE OF THE EQUITY SHARES.**

### RISKS TO INVESTORS

(For details refer to section titled "Risk Factors" on page 36 of the Prospectus)

- Geographical Risk:** We have our presence across 12 cities and towns across the states of West Bengal, Bihar, Assam, and Meghalaya, as of June 30, 2024. However, 95.48% of our Revenue from Operations in Fiscal 2024 was generated from West Bengal. Any event of a regional slowdown in the economic activity in West Bengal, could adversely affect our business and financial condition.
- Operational Risk:** Our credit rating was downgraded from CRISIL BBB+/Stable (Reaffirmed) in calendar year 2022 to CRISIL BB+/Stable (Issuer not cooperating) in calendar year 2023 and to CRISIL B/Stable (Issuer not cooperating) in calendar year 2024.
- The average cost of acquisition of Equity Shares held by the Selling Shareholders ranges from ₹0.00 to ₹100.21 per Equity Share, and the Offer Price at upper end of the Price Band is ₹441.
- Financial Risk:** As of Financial Year 2024, the market share of our Company in our major market which is East India is 1.15-1.30%. This is less than our peers like Dr. Lal Pathlabs which has a market share of 5.30-5.70% in its major market i.e. North India and Vijaya Diagnostics which has a market share of 2.20-2.50% in its major market, i.e. South India.
- Financial and Operational Risk:** B2B segment contributed 6.52% and 6.17% of the company's revenue which amounted to ₹ 39.59 million and ₹ 134.90 million in three months ending June 30, 2024 and financial year ending March 31, 2024 respectively. B2B revenue is dependent on long-term agreements with hospitals and public health agencies and any disruptions in these agreements could impact overall revenue.
- Offer Related Risk:** Our total offer is of 19,189,330 Equity Shares of face value of ₹ 2 each, aggregating to ₹ 8,462.49 million. The Offer is 100% offer for sale and accordingly, our Company will not receive any proceeds from the Offer. The Selling Shareholders will receive the entire proceeds from the Offer.
- Offer Related Risk:** The pre-offer shareholding of OrbiMed Asia II Mauritius Limited<sup>^</sup> is 33.35% and the post-offer shareholding of OrbiMed Asia II Mauritius Limited<sup>^</sup> will fall below 25% on a fully diluted basis. If the post-offer shareholding does not fall below 25%, the Offer will be withdrawn.  
<sup>^</sup>Surviving entity pursuant to amalgamation of OrbiMed Asia II Mauritius FDI Investments Limited (the erstwhile shareholder) into OrbiMed Asia II Mauritius Limited on November 11, 2022.
- Financial and Operational Risk:** B2C segment contributed 93.48% and 93.83% of the company's revenue which amounted to ₹ 567.72 million and ₹ 2,052.19 million in three months ending June 30, 2024 and financial year ending March 31, 2024 respectively. B2C revenue relies on brand reputation and attracting individual patients and any negative publicity could impact the overall revenue.
- Financial and Operational Risk:** A potential conflict of interest may occur between our Promoters, Directors, Subsidiaries and Group Companies that may have interest in companies, or may be entities, which are in the similar line of business as our Company like, (i) Suraksha Radiology Private Limited, Suraksha Specialty LLP, Suraksha Salvia LLP (investment by Suraksha Specialty LLP), and Asian Institute of Immunology and Rheumatology LLP, our Subsidiaries, have certain common pursuits with our Company; (ii) Suraksha Diagnostic & Eye Centre Private Limited, which is our Group Company. (iii) Dr. Somnath Chatterjee is a Director in one of our subsidiary.
- Risk related to Promoter and Promoter Group:** Our Promoters and certain members of our Promoter Group, namely Dr. Somnath Chatterjee, Ritu Mittal, Tinni Investments Limited, Dneema Overseas Private Limited, Sarla Kejriwal, pledged some of the Equity Shares in favour of Vistra ITCL (India) Limited. Upon creation, any invocation of such pledge could dilute the aggregate shareholding of our Promoters, and such members of our Promoter Group, which may cause a change in control of our Company and trigger an open offer requirement under the Takeover Regulations.
- Financial Risk:** The audit reports for the standalone and consolidated financial statements of our Company for Fiscals 2023 and 2024 include certain audit qualifications and emphasis of matters in relation to lack of appropriate audit evidence with respect to a vendor for capital goods inter alia its

- existence, validity of transactions, from whom procurements aggregated ₹ 9.58 million during the period from April 1, 2021 till March 31, 2024. As per the examination report dated October 21, 2024 issued by our Statutory Auditor, a report submitted by an independent firm of chartered accountants did not observe any negative findings other than the incorrect charge of GST for the above mentioned vendor, in respect of which GST has remained unrecovered.
- The securities of our promoter group companies, Akanksha Viniyog Limited and Senao International Limited were suspended due to non-compliance of listing regulations. Subsequently, the suspension was revoked and the Companies have applied for voluntary delisting with Calcutta Stock Exchange (CSE).
- Compliance Risk:** Our Company has filed compounding applications dated July 20, 2024 with the RoC, Kolkata at West Bengal for compounding of the offences for failure to appoint a whole-time Company Secretary for certain periods for which our Company was fined ₹0.48 million and our Promoters and Directors, Dr. Somnath Chatterjee and Ritu Mittal, paid a penalty of ₹0.34 million each and has filed an adjudication application dated July 23, 2024 with the ROC, due to non-filing of form 23 for which we were fined ₹ 0.2 million. Certain of our corporate records and filings are not traceable and may have inadvertent errors or inaccuracies.
- The weighted average cost of acquisition of all shares transacted in last three years, Last 18 months and one year, from the date of the Prospectus is as follows:

Period	Weighted average cost of acquisition (WACA) (in ₹)*	Lower End of the Price Band is 'X' times the WACA	Upper End of the Price Band is 'X' times the WACA	Range of acquisition price Lowest Price - Highest Price (in ₹)*
Last three years	49.29	8.52	8.95	0.00-100.21**
Last 18 months	49.29	8.52	8.95	0.00-100.21**
Last one year	49.29	8.52	8.95	0.00-100.21**

\*As certified by Manian and Rao, Chartered Accountants, pursuant to their certificate dated December 3, 2024.

\*\* The amount paid on the acquisition of CCPS has been considered as the basis for arriving at the cost of acquisition of Equity Shares on conversion of CCPS.

- The Price/Earnings ratio based on diluted EPS for FY 2024 for the issuer at the upper end of the Price band is as high as 99.55 as per FY 2024 as compared to the average industry peer group PE ratio of 79.65.
- The three Merchant Bankers associated with the issue have handled 72 public issues in the past three years out of which 21 issues closed below the issue price on listing date.

Name of the Book Running Lead Managers ("BRLMs")	Total Public Issues	Issues closed below Offer Price on listing date
ICICI Securities Limited*	33	8
Nuvama*	7	2
SBICAPS*	10	5
Common issues of above BRLMs	22	6
<b>Total</b>	<b>72</b>	<b>21</b>

\* Issues handled where there are no common BRLMs.

### BID/OFFER PERIOD:

**ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON : THURSDAY, NOVEMBER 28, 2024**  
**BID/OFFER OPENED ON : FRIDAY, NOVEMBER 29, 2024**  
**BID/OFFER CLOSED ON : TUESDAY, DECEMBER 3, 2024**

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer was allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs") ("QIB Portion"). Our Company in consultation with the Book Running Lead Managers, allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"). One-third of the Anchor Investor Portion was reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares were added to the QIB Portion (other than Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion was available for allocation on a proportionate basis only to Mutual Funds, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion was available for allocation on a proportionate basis to all QIBs, including Mutual Funds. Further, not less than 15% of the Offer was available for allocation to Non-Institutional Investors and not less than 35% of the Offer was available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. One-third of the Non-Institutional Portion was available for allocation to Non-Institutional Bidders with a Bid size of more than ₹ 0.20 million and up to ₹ 1.00 million and two-thirds of the Non-Institutional Portion was available for allocation to Non-Institutional Bidders with a Bid size of more than ₹ 1.00 million provided that under-subscription in either of these two sub-categories of the Non-Institutional Portion was allocated to Non-Institutional Bidders in the other sub-category of Non-Institutional Portion in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential Bidders (except Anchor Investors) were mandatorily required to participate in the Offer through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID in case of UPI Bidders, as applicable, pursuant to which their corresponding Bid Amount were blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Bank(s) under the UPI Mechanism, as the case may be, to the extent of the respective Bid Amounts. Anchor Investors were not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 418 of the Prospectus.

The bidding for Anchor Investor opened and closed on Thursday, November 28, 2024. The company received 16 applications from 12 anchor investors for 5,895,906 equity shares. The Anchor investor price was finalized at ₹ 441 per Equity Share. A total of 5,756,797 shares were allocated under the Anchor Investor Portion aggregating to ₹ 2,538,747,477.

The Offer received 140,231 applications for 22,867,788 Equity Shares (prior to rejections) resulting in 1.19169 times subscription. The details of the applications received in the Offer from various categories are as under: (before rejections):

Sr. No.	Category	No. of Applications Received*	No. of Equity Shares Applied	No. of Equity Shares available for allocation (as per Prospectus)	No. of times Subscribed	Amount (₹)
A	Retail Individual Bidders	137,146	6,251,580	6,716,266	0.93081	2,753,900,788.00
B	Non-Institutional Bidders - More than ₹0.20 million Up to ₹1.00 million	2,136	1,126,828	959,466	1.17443	495,320,874.00
C	Non-Institutional Bidders - Above ₹1.00 million	925	2,950,452	1,918,934	1.53755	1,301,101,494.00
E	Qualified Institutional Bidders (excluding Anchor Investors)	8	6,643,022	3,837,867	1.73092	2,929,572,702.00
F	Anchor Investors	16	5,895,906	5,756,797	1.02416	2,600,094,546.00
	<b>TOTAL</b>	<b>140,231</b>	<b>22,867,788</b>	<b>19,189,330</b>	<b>1.19169</b>	<b>10,079,990,404.00</b>

\* This excludes 2,865 applications for 131,274 Equity Shares aggregating to ₹ 57,844,472 from Retail Individual which were not in bid book but which were blocked.

### Final Demand

A summary of the final demand as at different Bid prices is as under:

Sr. No.	Bid Price (₹)	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % to Total
1	420	192,440	0.83	192,440	0.83
2	421	26,316	0.11	218,756	0.94
3	422	7,990	0.03	226,746	0.98
4	423	1,632	0.01	228,378	0.98
5	424	1,054	0.00	229,432	0.99
6	425	22,066	0.10	251,498	1.08
7	426	1,054	0.00	252,552	1.09
8	427	952	0.00	253,504	1.09
9	428	408	0.00	253,912	1.09
10	429	1,088	0.00	255,000	1.10
11	430	23,970	0.10	278,970	1.20
12	431	4,794	0.02	283,764	1.22
13	432	1,292	0.01	285,056	1.23
14	433	680	0.00	285,736	1.23
15	434	646	0.00	286,382	1.23
16	435	6,834	0.03	293,216	1.26
17	436	1,428	0.01	294,644	1.27
18	437	782	0.00	295,426	1.27
19	438	1,700	0.01	297,126	1.28
20	439	4,896	0.02	302,022	1.30
21	440	12,784	0.06	314,806	1.36
22	441	12,457,362	53.66	12,772,168	55.01
	CUTOFF	10,444,664	44.99	23,216,832	100.00
		<b>23,216,832</b>	<b>100.00</b>		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE on December 04, 2024.

Continued on next page.



...continued from previous page.

#### A. Allotment to Retail Individual Bidders (after rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Bidders, who have bid at the Cut-Off Price or at the Offer Price of ₹441 per Equity Share, was finalized in consultation with the BSE. This category has been subscribed to the extent of 0.88210 times. The total number of Equity Shares Allotted in Retail Portion is 5,924,432 Equity Shares to 130,103 successful Retail Individual Bidders. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	34	115,198	88.54	3,916,732	66.11	34	1 : 1	3,916,732
2	68	7,772	5.97	528,496	8.92	68	1 : 1	528,496
3	102	2,626	2.02	267,852	4.52	102	1 : 1	267,852
4	136	955	0.73	129,880	2.19	136	1 : 1	129,880
5	170	826	0.63	140,420	2.37	170	1 : 1	140,420
6	204	410	0.32	83,640	1.41	204	1 : 1	83,640
7	238	400	0.31	95,200	1.61	238	1 : 1	95,200
8	272	159	0.12	43,248	0.73	272	1 : 1	43,248
9	306	104	0.08	31,824	0.54	306	1 : 1	31,824
10	340	372	0.29	126,480	2.13	340	1 : 1	126,480
11	374	55	0.04	20,570	0.35	374	1 : 1	20,570
12	408	53	0.04	21,624	0.36	408	1 : 1	21,624
13	442	1,173	0.90	518,466	8.75	442	1 : 1	518,466
	<b>TOTAL</b>	<b>130,103</b>	<b>100.00</b>	<b>5,924,432</b>	<b>100.00</b>			<b>5,924,432</b>

Unsubscribed portion of 791,834 Equity Shares has been spilled over to QIB & NIB Categories in the ratio of 50:15.

#### B. Allotment to Non-Institutional Investors (More than ₹0.20 million Up to ₹1.00 million) (After Rejections)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹0.20 million Up to ₹1.00 million), who have bid at the Offer Price of ₹441 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 1.04628 times. The total number of Equity Shares allotted in this category is 1,020,376 Equity Shares (includes spilled over of 60,910 Equity Shares from Retail Category) to 2,043 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	476	1,812	88.69	862,512	80.79	476	1 : 1	862,512
2	510	41	2.01	20,910	1.96	493	1 : 1	20,213
3	544	15	0.73	8,160	0.76	510	1 : 1	7,650
4	578	10	0.49	5,780	0.54	527	1 : 1	5,270
5	612	5	0.24	3,060	0.29	544	1 : 1	2,720
6	646	4	0.20	2,584	0.24	562	1 : 1	2,248
7	680	32	1.57	21,760	2.04	579	1 : 1	18,528
8	714	4	0.20	2,856	0.27	596	1 : 1	2,384
9	748	2	0.10	1,496	0.14	613	1 : 1	1,226
10	782	1	0.05	782	0.07	630	1 : 1	630
11	816	2	0.10	1,632	0.15	647	1 : 1	1,294
12	850	5	0.24	4,250	0.40	664	1 : 1	3,320
13	884	7	0.34	6,188	0.58	681	1 : 1	4,767
14	918	6	0.29	5,508	0.52	699	1 : 1	4,194
15	952	20	0.98	19,040	1.78	716	1 : 1	14,320
16	986	1	0.05	986	0.09	733	1 : 1	733
17	1020	8	0.39	8,160	0.76	750	1 : 1	6,000
18	1054	4	0.20	4,216	0.39	767	1 : 1	3,068
19	1088	2	0.10	2,176	0.20	784	1 : 1	1,568
20	1122	31	1.52	34,782	3.26	801	1 : 1	24,831
21	1156	4	0.20	4,624	0.43	818	1 : 1	3,272
22	1190	2	0.10	2,380	0.22	836	1 : 1	1,672
23	1224	1	0.05	1,224	0.11	853	1 : 1	853
24	1326	1	0.05	1,326	0.12	904	1 : 1	904
25	1360	5	0.24	6,800	0.64	921	1 : 1	4,605
26	1428	3	0.15	4,284	0.40	955	1 : 1	2,865
27	1496	1	0.05	1,496	0.14	990	1 : 1	990
28	1530	1	0.05	1,530	0.14	1,007	1 : 1	1,007
29	1598	1	0.05	1,598	0.15	1,041	1 : 1	1,041
30	1802	1	0.05	1,802	0.17	1,144	1 : 1	1,144
31	1904	1	0.05	1,904	0.18	1,195	1 : 1	1,195
32	1938	1	0.05	1,938	0.18	1,212	1 : 1	1,212
33	2040	1	0.05	2,040	0.19	1,264	1 : 1	1,264
34	2176	1	0.05	2,176	0.20	1,332	1 : 1	1,332
35	2210	2	0.10	4,420	0.41	1,349	1 : 1	2,698
36	2244	5	0.24	11,220	1.05	1,366	1 : 1	6,830
	<b>Total</b>	<b>2,043</b>	<b>100.00</b>	<b>1,067,600</b>	<b>100.00</b>			<b>1,020,376</b>

Please Note : 1 additional Equity Share shall be allocated to 231 Successful Allottees from the categories 510 - 2244 (i.e. excluding successful applicants from Category 476) in the ratio of 16 : 231

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SURAKSHA DIAGNOSTIC LIMITED.

SURAKSHA DIAGNOSTIC LIMITED has filed the Prospectus with the RoC on December 3, 2024. The Prospectus is available on the website of SEBI at www.sebi.gov.in, on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.surakshanet.com/investor-relations and the websites of the Book Running Lead Managers ("BRLMs"), i.e. ICICI Securities Limited, Nuvama Wealth Management Limited and SBI Capital Markets Limited at www.icicisecurities.com, www.nuvama.com and www.sbicaps.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled 'Risk Factors' on page 36 of the Prospectus. Potential investors should not rely on the DRHP filed with SEBI.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. However, no offering of securities is being made in the United States.

#### C. Allotment to Non-Institutional Investors (more than ₹1.00 million) (After Rejections)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹1.00 million), who have bid at the Offer Price of ₹441 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 1.43125 times. The total number of Equity Shares allotted in this category is 2,040,755 Equity Shares (includes spilled over of 121,821 Equity Shares from Retail Category) to 912 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	2278	864	94.74	1,968,192	67.38	1,640	1 : 1	1,416,960
						1	55 : 216	220
2	2312	2	0.22	4,624	0.16	1,662	1 : 1	3,324
3	2346	2	0.22	4,692	0.16	1,684	1 : 1	3,368
4	2380	2	0.22	4,760	0.16	1,706	1 : 1	3,412
5	2720	1	0.11	2,720	0.09	1,926	1 : 1	1,926
6	2856	2	0.22	5,712	0.20	2,014	1 : 1	4,028
7	2924	1	0.11	2,924	0.10	2,058	1 : 1	2,058
8	3060	2	0.22	6,120	0.21	2,145	1 : 1	4,290
9	3196	1	0.11	3,196	0.11	2,233	1 : 1	2,233
10	3366	1	0.11	3,366	0.12	2,343	1 : 1	2,343
11	3400	6	0.66	20,400	0.70	2,365	1 : 1	14,190
12	3434	1	0.11	3,434	0.12	2,387	1 : 1	2,387
13	4080	1	0.11	4,080	0.14	2,804	1 : 1	2,804
14	4556	1	0.11	4,556	0.16	3,112	1 : 1	3,112
15	4760	2	0.22	9,520	0.33	3,244	1 : 1	6,488
16	5100	2	0.22	10,200	0.35	3,464	1 : 1	6,928
17	5440	1	0.11	5,440	0.19	3,683	1 : 1	3,683
18	5712	3	0.33	17,136	0.59	3,859	1 : 1	11,577
19	6800	1	0.11	6,800	0.23	4,562	1 : 1	4,562
20	6834	1	0.11	6,834	0.23	4,584	1 : 1	4,584
21	7752	1	0.11	7,752	0.27	5,177	1 : 1	5,177
22	9112	1	0.11	9,112	0.31	6,056	1 : 1	6,056
23	11322	1	0.11	11,322	0.39	7,483	1 : 1	7,483
24	11356	1	0.11	11,356	0.39	7,505	1 : 1	7,505
25	11390	1	0.11	11,390	0.39	7,527	1 : 1	7,527
26	13668	1	0.11	13,668	0.47	8,999	1 : 1	8,999
27	17680	1	0.11	17,680	0.61	11,591	1 : 1	11,591
28	18224	1	0.11	18,224	0.62	11,943	1 : 1	11,943
29	22780	1	0.11	22,780	0.78	14,886	1 : 1	14,886
30	23800	1	0.11	23,800	0.81	15,545	1 : 1	15,545
31	45356	1	0.11	45,356	1.55	29,472	1 : 1	29,472
32	47600	1	0.11	47,600	1.63	30,922	1 : 1	30,922
33	164390	1	0.11	164,390	5.63	106,379	1 : 1	106,379
34	183702	1	0.11	183,702	6.29	118,856	1 : 1	118,856
35	238000	1	0.11	238,000	8.15	153,937	1 : 1	153,937
	<b>TOTAL</b>	<b>912</b>	<b>100.00</b>	<b>2,920,838</b>	<b>100.00</b>			<b>2,040,755</b>

Please Note : 1 additional Equity Share shall be allocated to Category 2278 in the ratio of 55 : 216

#### D. Allotment to QIBs

Allotment to QIBs, who have Bid at the Offer Price of ₹441 per Equity Share or above, has been done on a proportionate basis in consultation with the BSE. This category has been subscribed to the extent of 1.49383 times of QIB Portion. As per the SEBI Regulations, Mutual Funds were Allotted 5% of the Equity Shares of QIB Portion available i.e., 222,348 (Includes spilled over of 30,455 Equity Shares from Retail Category) Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were Allotted the remaining available Equity Shares i.e., 4,224,622 Equity Shares (Includes spilled over of 578,648 Equity Shares from Retail Category) on a proportionate basis. The total number of Equity Shares Allotted in the QIB Portion is 4,446,970 Equity Shares, which were allotted to 8 successful QIB Investors. The category-wise details of the Basis of Allotment are as under:

Category	FI'S/BANK'S	MFS	IC'S	NBFC'S	AIF	FPC/FII	Others	Total
QIB	522,207	3,392,735	14,899	-	-	442,566	74,563	4,446,970

#### E. Allotment to Anchor Investors

The Company, in consultation with the BRLMs, have allocated 5,756,797 Equity Shares to 12 Anchor Investors (through 16 Applications) at the Anchor Investor Offer Price of ₹441 per Equity Share in accordance with the SEBI Regulations. This represents 60% of the QIB Portion.

Category	FI'S/BANK'S	MFS	IC'S	NBFC'S	AIF	FPC/FII	OTHERS	Total
ANCHOR	-	3,877,632	-	-	881,367	997,798	-	5,756,797

The IPO Committee of our Company on Wednesday, December 04, 2024 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being BSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum-Intimations and/ or notices have been dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Public Issue Account have been issued on Wednesday, December 04, 2024 and payment to non-syndicate brokers have been issued on Thursday, December 05, 2024. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on Thursday, December 05, 2024 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company has filed the Listing application with BSE and NSE on Thursday, December 05, 2024. The Company has received listing and trading approval from BSE and NSE and the trading is expected to commence on Friday, December 06, 2024.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

#### INVESTORS PLEASE NOTE

The details of the allotment made will be hosted on the website of the Registrar to the Offer, **KFin Technologies Limited** at www.kfintech.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:

**KFin Technologies Limited**  
Selenium Tower B, Plot No. 31 and 32, Financial District, Nanakramguda,  
Serilingampally, Hyderabad -500 032, Telangana, India.  
Telephone Number: +91 40 6716 2222; Toll Free No.: 18003094001  
Website: www.kfintech.com; Investor Grievance E-mail: einward.ris@kfintech.com  
Email : sdl ipo@kfintech.com; Contact person: M. Murali Krishna  
SEBI Registration Number: INR000000221

For SURAKSHA DIAGNOSTIC LIMITED

On behalf of the Board of Directors

Sd/-

Mamta Jain

Company Secretary and Compliance Officer

Place: Kolkata  
Date: December 5, 2024